Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of NNC0363-0845 in Type 1 Diabetes
NCT05134987Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Dec 2021
- Primary completion
- May 2022
- Modality
- Recombinant Proteins and Enzymes, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of NNC0363-0845 in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Area Under the Plasma Glucose-Time Curve at Steady Concentrations (0.5-2h). Started Dec 2021; status: completed.
02
Drugs
NNC0363-0845
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT05134987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05134987.